Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 126
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Pharmazie ; 78(8): 141-149, 2023 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-37592417

RESUMEN

This study aimed to investigate adverse reactions to medications administered during palliative care and compare the responses of Board-Certified Pharmacists in Palliative Pharmacy (BCPPP) and non-BCPPP professionals. Methods: This multicentre prospective survey included hospital and community pharmacists who are members of the Japanese Society for Pharmaceutical Palliative Care and Sciences. Study participants included patients who experienced new drug reactions during the study period and responded to the requested survey items. The follow-up period for each eligible patient began on the day the pharmacists initiated the intervention and ended at discharge, death, or after one month of intervention. The primary endpoint was the impact of pharmacist intervention on adverse drug reactions. The pharmacists included in the study evaluated the severity of adverse drug reactions to assess the effect of their intervention using an integrated palliative care outcome scale before and after the intervention. Key findings: During the survey period, 79 adverse drug reaction intervention reports from 69 patients were obtained from 54 pharmacists (28 certified and 26 non-certified). The response rate was 1.62% (54/3,343). The management of palliative pharmacotherapy side effects by BCPPP and non-BCPPP significantly improved the patients' activities of daily living (P < 0.001). The BCPPP group intervened for significantly more patients with adverse drug reactions and overall adverse drug reactions than the non-BCPPP group (P < 0.023 and P < 0.013, respectively). Conclusion: BCPPP interventions can improve symptom management.


Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Cuidados Paliativos , Humanos , Farmacéuticos , Actividades Cotidianas , Proyectos Piloto , Estudios Prospectivos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología
2.
Science ; 245(4921): 965-7, 1989 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-2772648

RESUMEN

The structure and function of transcription factors of higher plants was studied by isolating cDNA clones encoding a wheat sequence-specific DNA binding protein. A hexameric nucleotide motif, ACGTCA, is located upstream from the TATA box of several plant histone genes. It has been suggested that this motif is essential for efficient transcription of the wheat histone H3 gene. A wheat nuclear protein, HBP-1 (histone DNA binding protein-1), which specifically binds to the hexameric motif, has previously been identified as a putative transcription factor. A cDNA clone encoding HBP-1 has been isolated on the basis of specific binding of HBP-1 to the hexameric motif. The deduced amino acid sequence indicates that HBP-1 contains the leucine zipper motif, which represents a characteristic property of several eukaryotic transcription factors.


Asunto(s)
Proteínas de Unión al ADN/genética , Genes , Histonas/genética , Leucina , Proteínas Nucleares/genética , Plantas/genética , Transcripción Genética , Secuencia de Aminoácidos , Secuencia de Bases , Clonación Molecular , ADN/genética , Genes Reguladores , Sistemas de Información , Metilación , Datos de Secuencia Molecular , Hibridación de Ácido Nucleico , Triticum/genética
3.
Horm Metab Res ; 41(12): 861-5, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19672814

RESUMEN

It is well known that parathyroid hormone (PTH) possesses an anabolic effect on bone. However, the mechanisms are not fully elucidated. So far, it is unclear whether or not PTH could stimulate the expression of bone morphogenetic protein-2 (BMP-2), a strong mediator for bone formation. Growing evidence suggests that BMP-2 expression is regulated by the mevalonate pathway and Rho-associated protein kinase (ROK) activity. This study was performed to examine if PTH affects BMP-2 expression and to clarify its involvement of the mevalonate pathway. Osteoblastic MC3T3-E1 cells were treated with human PTH-(1-34) to determine BMP-2 mRNA expression levels by real-time PCR and to measure the ROK activity by the kinase assay. Incubation with 10 (-9)-10 (-8) M of hPTH-(1-34) for 6 h induced significant upregulation of BMP-2 mRNA levels in MC3T3-E1 cells. Short-term treatment of hPTH-(1-34) suppressed Rho kinase activity and mevalonate kinase mRNA levels. PTH-induced BMP-2 mRNA upregulation was selectively reversed by geranylgeranyl pyrophosphate (GGPP) pretreatment, but not by mevalonate pretreatment. These findings suggest that BMP-2 mRNA expression was upregulated by PTH in MC3T3-E1 cells mediated by mevalonate pathway suppression followed by ROK inhibition. We have now demonstrated for the first time that PTH stimulated BMP-2 mRNA expression via the mevalonate pathway and ROK in osteoblastic MC3T3-E1 cells.


Asunto(s)
Proteína Morfogenética Ósea 2/genética , Osteoblastos/efectos de los fármacos , Osteoblastos/enzimología , Hormona Paratiroidea/farmacología , Fosfotransferasas (Aceptor de Grupo Alcohol)/antagonistas & inhibidores , Regulación hacia Arriba/efectos de los fármacos , Quinasas Asociadas a rho/antagonistas & inhibidores , Animales , Proteína Morfogenética Ósea 2/metabolismo , Línea Celular , Relación Dosis-Respuesta a Droga , Humanos , Ratones , Modelos Biológicos , Fosfotransferasas (Aceptor de Grupo Alcohol)/genética , Fosfotransferasas (Aceptor de Grupo Alcohol)/metabolismo , Fosfatos de Poliisoprenilo/farmacología , Inhibidores de Proteínas Quinasas/farmacología , ARN Mensajero/genética , ARN Mensajero/metabolismo , Factores de Tiempo
4.
Int J Obes (Lond) ; 32(12): 1841-7, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18936764

RESUMEN

BACKGROUND: Several studies have reported increased fat oxidation with diacylglycerol (DAG) oil consumption. However, the effects of long-term DAG oil consumption on energy metabolism remain to be investigated. OBJECTIVE: The objective of this study was to compare the effects of 14 days of either DAG or triacylglycerol (TAG) oil consumption on substrate oxidation, energy expenditure (EE) and dietary fat oxidation. DESIGN: Eight males and six females participated in this randomized, double-blind, crossover feeding study. Each patient consumed the 14-day controlled test diet containing either 10 g day(-1) of DAG or TAG oil for acclimatization before a respiratory chamber measurement, followed by a 2-week washout period between diet treatments. Substrate oxidation and EE were measured in the respiratory chamber at the end of each dietary treatment. The patients consumed test oil as 15% of total caloric intake in the respiratory chamber (mean test oil intake was 36.1+/-6.6 g day(-1)). RESULTS: Twenty-four hour fat oxidation was significantly greater with 14 days of DAG oil consumption compared with TAG oil consumption (78.6+/-19.6 and 72.6+/-14.9 g day(-1), respectively, P<0.05). There were no differences in body weight or body composition between diet treatments. Dietary fat oxidation was determined using the recovery rate of (13)CO(2) in breath, and was significantly enhanced with DAG oil consumption compared with TAG oil consumption, measured over 22 h after ingestion of (13)C-labelled triolein. Resting metabolic rate (RMR) was significantly greater with DAG oil consumption compared with TAG oil consumption (1766+/-337 and 1680+/-316 kcal day(-1), respectively, P<0.05). CONCLUSION: Consumption of DAG oil for 14 days stimulates both fat oxidation and RMR compared with TAG oil consumption, which may explain the greater loss of body weight and body fat with DAG oil consumption that has been observed in weight-loss studies.


Asunto(s)
Tejido Adiposo/efectos de los fármacos , Grasas de la Dieta/metabolismo , Diglicéridos/farmacología , Metabolismo Energético/efectos de los fármacos , Aceites de Plantas/farmacología , Triglicéridos/farmacología , Adulto , Pruebas Respiratorias , Dióxido de Carbono/química , Estudios Cruzados , Diglicéridos/administración & dosificación , Método Doble Ciego , Ácidos Grasos Monoinsaturados , Femenino , Alimentos , Humanos , Masculino , Persona de Mediana Edad , Sobrepeso/metabolismo , Oxidación-Reducción , Aceites de Plantas/administración & dosificación , Aceite de Brassica napus , Aceite de Cártamo/farmacología , Aceite de Soja/farmacología , Tokio , Triglicéridos/administración & dosificación , Ácido alfa-Linolénico/farmacología
5.
Parasitology ; 135(3): 295-301, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18039413

RESUMEN

Cryptosporidium parvum is an intracellular protozoan parasite belonging to the phylum Apicomplexa, and a major cause of waterborne gastroenteritis throughout the world. Invasive zoites of apicomplexan parasites, including C. parvum, are thought to have characteristic organelles on the apical apex; however, compared with other parasites, the cytoskeletal ultrastructure of C. parvum zoites is poorly understood. Thus, in the present study, we ultrastructurally examined C. parvum sporozoites using electron microscopy to clarify the framework of invasive stages. Consequently, at the apical end of sporozoites, 3 apical rings and an electron-dense collar were seen. Two thick central microtubules were seen further inside sporozoites and extended to the posterior region. Using anti-alpha and -beta tubulin antibodies generated from sea urchin and rat brain, both antibodies cross-reacted at the apical region of sporozoites in immunofluorescent morphology. The molecular mass of C. parvum alpha tubulin antigen was 50 kDa by Western blotting and the observed apical cytoskeletal structures were shown to be composed of alpha tubulin by immunoelectron microscopy. These results suggested that C. parvum sporozoites were clearly different in their cytoskeletal structure from those of other apicomplexan parasites.


Asunto(s)
Cryptosporidium parvum/ultraestructura , Citoesqueleto/ultraestructura , Tubulina (Proteína)/análisis , Animales , Western Blotting/métodos , Técnica del Anticuerpo Fluorescente Indirecta/métodos , Microscopía Electrónica de Transmisión/métodos , Microscopía Inmunoelectrónica/métodos , Microtúbulos/ultraestructura , Peso Molecular , Esporozoítos/química , Esporozoítos/ultraestructura , Tubulina (Proteína)/ultraestructura
6.
Br J Ophthalmol ; 90(6): 765-8, 2006 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16464967

RESUMEN

BACKGROUND/AIMS: Chemokines are key molecules that initiate leucocyte infiltration to the inflammatory site. The involvement of chemokines in uveitis is well studied, yet the source of this molecule in the inflamed eye is not clearly identified. The possible sources of chemokines are ocular resident cells or the inflammatory cells infiltrated to the eye. Here the authors examined whether ocular infiltrating T cells of uveitis patients do produce chemokines. METHODS: T cell clones (TCCs) were established from ocular infiltrating cells of patients with non-infectious uveitis. TCCs were characterised using flow cytometry. Spontaneous production of chemokines by TCCs was evaluated by ELISA. RESULTS: TCCs from ocular infiltrating cells were revealed to be memory activated Th1 type CD4 positive cells. Those TCCs produced larger amounts of chemokines than TCCs from peripheral blood mononuclear cells of uveitis or healthy donors. CONCLUSIONS: The present data indicate that ocular infiltrating T cells of patients with non-infectious uveitis produce chemokines and recruit further infiltrating lymphoid cells. Such T cells may have roles in the prolonged/chronic state of non-infectious uveitis.


Asunto(s)
Quimiocinas/biosíntesis , Células TH1/inmunología , Uveítis/inmunología , Enfermedad Aguda , Humor Acuoso/inmunología , Síndrome de Behçet/inmunología , Citometría de Flujo/métodos , Humanos , Inmunofenotipificación , Leucocitos Mononucleares/inmunología , Sarcoidosis/inmunología , Uveítis Anterior/inmunología , Síndrome Uveomeningoencefálico/inmunología
7.
Transplant Proc ; 48(7): 2262-2266, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27742275

RESUMEN

BACKGROUND: With the increased demand for kidney transplants and the short supply of organs, it is necessary to have a better strategy to evaluate the available organs, especially from donors with acute kidney injury (AKI), because these organs are often rejected for transplantation. METHODS: We evaluated patients undergoing transplantation with kidneys from deceased donors with AKI. The cases were divided into AKI stages according to the Acute Kidney Injury Network (AKIN) criteria. The outcomes examined were delayed graft function (DGF), creatinine (Cr), and creatinine clearance (CrCl) at 6 months after transplantation. RESULTS: We evaluated 101 patients and included 53 in the final model. There was no statistical difference in the demographic characteristics, comorbidities, and immunosuppression according to each AKIN stage, showing a population of homogeneous transplant recipients. Recipients in AKIN stages I, II, and III, respectively had DGF in 72.7%, 61.9%, and 71.4% of cases; Cr of 1.6 ± 0.5, 1.7 ± 0.7, and 1.6 ± 0.2 mg/dL at 6 months; and CrCl of 60.6 ± 22.4, 52.4 ± 27.4, and 52.03 ± 12.1 mL/min at 6 months. Each additional year in donor age increased the relative risk of DGF by 1.08 (1.0-1.13) (P = .01), and organs from older donors were associated with worse renal function at 6 months. CONCLUSION: Kidney transplantation of organs from deceased donors with AKI showed greater DGF but good outcomes. Donor age was the only characteristic that correlated with outcome.


Asunto(s)
Lesión Renal Aguda , Trasplante de Riñón/métodos , Donantes de Tejidos , Lesión Renal Aguda/fisiopatología , Adulto , Factores de Edad , Anciano , Funcionamiento Retardado del Injerto/epidemiología , Funcionamiento Retardado del Injerto/etiología , Femenino , Supervivencia de Injerto , Humanos , Trasplante de Riñón/efectos adversos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Donantes de Tejidos/provisión & distribución
8.
J Neuroimmunol ; 168(1-2): 118-27, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16154209

RESUMEN

Suppressors of cytokine signaling (SOCS) are implicated in immunopathogenic mechanisms of autoimmune diseases. We show here that SOCS expression in retina is temporarily correlated with progression of experimental autoimmune uveitis (EAU), an organ-specific autoimmune disease that serves as model of human uveitis. Peak of EAU correlates with highest SOCS genes expression while disease resolution coincides with their down-regulation. Surprisingly, SOCS5 is constitutively expressed in retina. SOCS5 expression increases significantly during EAU and remains elevated even after disease resolution. Our data suggest that cytokine-inducible SOCS members may be involved in negative regulation of inflammatory cytokines activities during EAU, while constitutively expressed SOCS5 may have neuroprotective functions.


Asunto(s)
Citocinas/metabolismo , Fármacos Neuroprotectores/uso terapéutico , Retina/efectos de los fármacos , Transducción de Señal/fisiología , Proteínas Supresoras de la Señalización de Citocinas/uso terapéutico , Uveítis/metabolismo , Animales , Western Blotting/métodos , Antígenos CD4/metabolismo , Proliferación Celular , Citocinas/genética , Modelos Animales de Enfermedad , Ensayo de Cambio de Movilidad Electroforética/métodos , Ensayo de Inmunoadsorción Enzimática/métodos , Expresión Génica/efectos de los fármacos , Ratones , Fármacos Neuroprotectores/farmacología , ARN Mensajero/biosíntesis , Retina/metabolismo , Retina/fisiología , Proteínas de Unión al Retinol , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Proteínas Supresoras de la Señalización de Citocinas/farmacología , Linfocitos T/metabolismo , Factores de Tiempo , Uveítis/inducido químicamente , Uveítis/prevención & control
9.
Endocrinology ; 118(5): 1787-94, 1986 May.
Artículo en Inglés | MEDLINE | ID: mdl-3084207

RESUMEN

Serum triglyceride and very low density lipoprotein (VLDL) concentrations were higher in male spontaneously hypertensive rat than in male control Wistar Kyoto rat, whereas serum cholesterol, phospholipids, and high density lipoprotein (HDL) concentrations were lower. Castration of hypertensive rats induced an increase in serum cholesterol, phospholipids, and HDL, and a decrease in serum triglyceride and VLDL. The cholesterol content of HDL increased, whereas the triglycerides decreased after gonadectomy of hypertensive rats. These changes in serum lipids and lipoproteins could be reversed by the administration of testosterone. Apolipoprotein E contents in VLDL and HDL of hypertensive rats were low when compared with control rats but rose after castration and could be reduced by testosterone administration. Hypertensive rats accumulated triglycerides and cholesterol in the liver, which resulted in an increase of liver weight. Castration reduced the hepatic lipids as well as liver weight. The effects of castration and testosterone treatment on lipids and lipoproteins were more prominent in spontaneously hypertensive rats than in control rats. These results suggest that testosterone reduces VLDL catabolism which is related to changes of apolipoprotein composition, and that hypertensive rats are more sensitive to testosterone than control rats.


Asunto(s)
Apolipoproteínas/sangre , Hipertensión/sangre , Lipoproteínas/sangre , Orquiectomía , Testosterona/farmacología , Animales , Apolipoproteína A-I , Apolipoproteínas A/sangre , Apolipoproteínas C/sangre , Apolipoproteínas E/sangre , Colesterol/sangre , Metabolismo de los Lípidos , Lipoproteínas HDL/sangre , Lipoproteínas LDL/sangre , Lipoproteínas VLDL/sangre , Hígado/anatomía & histología , Hígado/metabolismo , Masculino , Tamaño de los Órganos/efectos de los fármacos , Fosfolípidos/sangre , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas WKY , Triglicéridos/sangre
10.
Hypertension ; 25(4 Pt 2): 739-43, 1995 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7721425

RESUMEN

We studied the effects of the selective endothelin A receptor antagonist FR139317 and the combined endothelin A/endothelin B receptor antagonist bosentan in rat mesenteric arteries by using a video dimension analyzer. In endothelium-denuded arteries, increasing concentrations of endothelin-1 evoked a biphasic vasoconstriction. The first phase was observed at low concentrations (10(-16) to 10(-11) mol/L) of endothelin-1 and was relatively weak. However, the contractions characterizing the second phase, which occurred at higher concentrations (10(-10) to 3 x 10(-8) mol/L) of endothelin-1, were much stronger. FR139317 concentration-dependently shifted the second phase of the endothelin-1-induced contraction curve to the right without affecting the first phase. In contrast, bosentan inhibited both the first and the second phase. Even after the blockade of endothelin A receptor, increasing concentrations of the endothelin B receptor agonists endothelin-3 and sarafotoxin S6c still induced small contractions. Maximal contractions induced by single-bolus extraluminal application of endothelin-3 (10(-9) mol/L) or sarafotoxin S6c (3 x 10(-8) mol/L) were markedly more pronounced than responses induced by cumulative concentrations, suggesting endothelin B receptor downregulation upon repeated and sustained activation. The response induced by a single bolus of endothelin-3 (10(-9) mol/L) was antagonized by bosentan but not by FR139317, confirming that endothelin B receptors were involved. In endothelium-intact arteries half-maximally precontracted with norepinephrine, bosentan but not FR139317 inhibited the relaxations induced by intraluminally applied endothelin-3. (ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Arterias/metabolismo , Azepinas/farmacología , Antagonistas de los Receptores de Endotelina , Indoles/farmacología , Receptores de Endotelina/metabolismo , Sulfonamidas/farmacología , Animales , Arterias/efectos de los fármacos , Bosentán , Endotelinas/farmacología , Masculino , Ratas , Ratas Endogámicas WKY , Receptores de Endotelina/clasificación , Circulación Esplácnica/efectos de los fármacos , Vasoconstricción/efectos de los fármacos , Vasoconstrictores/farmacología , Venenos de Víboras/farmacología
11.
Hypertension ; 26(5): 744-51, 1995 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-7591013

RESUMEN

Nitric oxide is an important regulator of vascular function and blood pressure. Chronic administration of nitric oxide inhibitors provides a new model of hypertension with pronounced target organ damage. We investigated the effects of oral treatment with N omega-nitro-L-arginine methyl ester (L-NAME) for 6 weeks on vascular reactivity of the aorta in Wistar-Kyoto rats. Certain rats received verapamil or trandolapril in addition to L-NAME. Systolic blood pressure increased in the L-NAME group (by approximately or equal to 80 mm Hg systolic) but not in controls or rats treated with verapamil or trandolapril. Isometric tension changes of aortic rings were recorded. Endothelium-dependent relaxations to acetylcholine were reduced in the L-NAME group (58 +/- 6% versus 104 +/- 1% in placebo, P < .05) but were normalized by treatment with verapamil or trandolapril. In contrast, endothelium-independent relaxations to sodium nitroprusside were not significantly reduced in L-NAME hypertension but were slightly enhanced by trandolapril therapy (P < .05) in the L-NAME group only. In quiescent rings, acetylcholine caused endothelium-dependent contractions in particular after in vitro incubation with L-NAME. These contractions tended to be enhanced in L-NAME hypertension (23 +/- 4% versus 14 +/- 3% in the placebo group; P = NS) and were significantly reduced after treatment with verapamil or trandolapril (P < .05). Concentrations to norepinephrine and angiotensin I and II were unaffected by L-NAME hypertension, whereas those to endothelin-1 were reduced (P < .05).(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Aorta/fisiopatología , Endotelio Vascular/fisiopatología , Hipertensión/fisiopatología , Músculo Liso Vascular/fisiopatología , Vasoconstricción/efectos de los fármacos , Acetilcolina/farmacología , Animales , Antihipertensivos/uso terapéutico , Aorta/metabolismo , Arginina/análogos & derivados , Presión Sanguínea/efectos de los fármacos , Endotelio Vascular/metabolismo , Inhibidores Enzimáticos , Hipertensión/inducido químicamente , Hipertensión/metabolismo , Hipertensión/prevención & control , Indoles/uso terapéutico , Músculo Liso Vascular/metabolismo , NG-Nitroarginina Metil Éster , Óxido Nítrico Sintasa/antagonistas & inhibidores , Ratas , Ratas Endogámicas WKY , Vasodilatadores/uso terapéutico , Verapamilo/uso terapéutico
12.
Hypertension ; 29(3): 763-9, 1997 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9052893

RESUMEN

Because nitric oxide inhibits the synthesis and vasoconstrictor effect of endothelin-1, the effect of endothelin-1 may be enhanced under conditions of chronic inhibition of nitric oxide synthesis. We studied the effect of chronic therapy with bosentan, a combined endothelin-A/endothelin-B receptor antagonist, on blood pressure and vascular function and structure of small arteries as well as on the reactivity of the aorta in N(omega)-nitro-L-arginine methyl ester (L-NAME)-induced hypertension. Six-week-old Wistar-Kyoto rats were randomly treated for 6 weeks with placebo (control), L-NAME (70 mg/kg per day), or L-NAME plus bosentan (100 mg/kg per day). The treatments were stopped 2 to 3 days before the in vitro experiments so that only the long-term effects of the drugs could be observed. L-NAME increased systolic blood pressure: bosentan did not prevent this effect although the initial blood pressure rise was delayed (P=NS versus L-NAME group). Bosentan administration did not modify the structural alteration of the resistance vessels induced by L-NAME, nor did it improve endothelium-dependent relaxation of resistance vessels or the aorta. However, bosentan therapy markedly increased endothelium-dependent contraction to acetylcholine, which was slightly enhanced by L-NAME. In contrast, bosentan inhibited aortic endothelium-dependent contractions when applied acutely in vitro. This observation, together with the increased maximal vasoconstriction to the thromboxane A2 receptor agonist U46619 after 2 weeks of bosentan administration, suggests that bosentan also interacts with the receptors mediating endothelium-dependent contractions. In conclusion, our experiments suggest a minor role of endothelin in chronic L-NAME-induced hypertension as well as in the concomitant alterations of vascular structure.


Asunto(s)
Antagonistas de los Receptores de Endotelina , Inhibidores Enzimáticos/farmacología , Hipertensión/tratamiento farmacológico , Músculo Liso Vascular/efectos de los fármacos , Músculo Liso Vascular/metabolismo , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico/fisiología , Sulfonamidas/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Bosentán , Interacciones Farmacológicas , Hemodinámica/efectos de los fármacos , Masculino , Ratas , Ratas Endogámicas WKY , Vasoconstricción/efectos de los fármacos
13.
Hypertension ; 29(1 Pt 2): 435-41, 1997 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9039139

RESUMEN

Angiotensin II, a constrictor and mitogen of vascular smooth muscle cells, affects the release of endothelium-derived factors such as nitric oxide or endothelin-1. This study investigated the influence of endothelin-1, using the selective endothelin A receptor antagonist LU135252, on blood pressure and endothelial function in angiotensin II-induced hypertension in the rat. Two weeks of angiotensin II administration (200 ng/kg per minute) increased systolic blood pressure (+35 +/- 5 mm Hg; tail-cuff method) compared with placebo (P < .05). LU135252 alone did not affect systolic pressure but lowered the angiotensin II-induced pressure increase (P < .05). In isolated aortic rings, endothelium-dependent relaxations to acetylcholine were reduced in the angiotensin II group (P < .05 versus placebo) and improved by concomitant chronic LU135252 treatment (P < .05 versus angiotensin II). Blood pressure elevation strongly correlated with impaired endothelium-dependent relaxations to acetylcholine (r = -.967). LU135252 did not affect endothelium-independent relaxations to sodium nitroprusside, which were diminished after angiotensin II treatment (P < .05). In quiescent rings, chronic angiotensin II administration enhanced endothelium-dependent contractions to acetylcholine, which were reduced by LU135252 (P < .05). Impaired contractions to endothelin-1 and norepinephrine in the angiotensin II group were normalized after treatment with LU135252 (P < .05). Thus, chronic therapy with LU135252 partially prevents angiotensin II-induced hypertension and the alternations of the endothelial function observed in this experimental model.


Asunto(s)
Antagonistas de los Receptores de Endotelina , Endotelina-1/sangre , Endotelio Vascular/efectos de los fármacos , Hipertensión/inducido químicamente , Relajación Muscular/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Acetilcolina/farmacología , Angiotensina II/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Endotelio Vascular/fisiología , Hipertensión/fisiopatología , Masculino , Músculo Liso Vascular/fisiología , Ratas , Ratas Endogámicas WKY , Tromboxano A2/análogos & derivados , Tromboxano A2/farmacología , Vasoconstrictores/farmacología
14.
Hypertension ; 27(1): 25-31, 1996 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8591883

RESUMEN

The objective of this study was to examine the effects of long-term antihypertensive therapy on blood pressure and vascular responses of resistance arteries during prolonged inhibition of nitric oxide synthesis. Four groups of 6-week-old Wistar-Kyoto rats were treated with either placebo as controls or N omega-nitro-L-arginine methyl ester (L-NAME) alone or in combination with verapamil or with trandolapril. Drugs were given orally for 6 weeks or short-term in vitro to vessels obtained from untreated rats. Endothelium-dependent and -independent relaxations as well as contractions were studied in isolated perfused mesenteric and renal arteries with an arteriograph. Kidney nitric oxide synthase activity was also evaluated. Verapamil and trandolapril prevented the increase in systolic blood pressure and the blunted acetylcholine-induced relaxations that occurred with L-NAME treatment without improving the nitric oxide synthase activity. Both antihypertensive regimens also normalized sensitivity to sodium nitroprusside, which was enhanced by L-NAME. In contrast, short-term in vitro preincubation with verapamil or trandolaprilat in the presence of L-NAME did not improve the impaired relaxations to acetylcholine. Long-term but not short-term therapy with a calcium antagonist or angiotensin-converting enzyme inhibitor improved the blunted endothelium-dependent relaxations in nitric oxide-deficient hypertension. These findings strongly suggest that the role of other vasodilator systems, which normally do not regulate vascular tone, is enhanced with long-term but not short-term treatment with these drugs. These observations emphasize the potential importance of these treatments in the management of hypertension in which nitric oxide production is diminished.


Asunto(s)
Antihipertensivos/farmacología , Endotelio Vascular/efectos de los fármacos , Indoles/farmacología , Óxido Nítrico/metabolismo , Animales , Arginina/análogos & derivados , Arginina/farmacología , Presión Sanguínea/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Endotelio Vascular/fisiología , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Arterias Mesentéricas/efectos de los fármacos , Arterias Mesentéricas/enzimología , Arterias Mesentéricas/fisiología , NG-Nitroarginina Metil Éster , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/metabolismo , Ratas , Ratas Endogámicas WKY , Arteria Renal/efectos de los fármacos , Arteria Renal/enzimología , Arteria Renal/fisiología , Factores de Tiempo , Vasoconstricción , Vasodilatación , Verapamilo/farmacología
15.
FEBS Lett ; 256(1-2): 67-70, 1989 Oct 09.
Artículo en Inglés | MEDLINE | ID: mdl-2680601

RESUMEN

A novel DNA-binding protein that specifically interacts with the hexameric sequence ACGTCA in the regulatory region of the wheat histone H3 gene has been identified in wheat nuclear extract and designated HBP-1a. The nuclear protein HBP-1 previously identified as a DNA-binding protein that interacts with hexameric sequences in the H3, cauliflower mosaic virus (CaMV) 35 S RNA, and nopaline synthase (NOS) promoter regions therefore has been renamed HBP-1b. The flanking sequences that surround the hexameric sequence may account for the difference in the binding properties of HBP-1a and HBP-1b.


Asunto(s)
Proteínas de Unión al ADN/análisis , Genes Reguladores , Proteínas Nucleares/análisis , Plantas/genética , Regiones Promotoras Genéticas , Factores de Transcripción/análisis , Unión Competitiva , Histonas/genética , Técnicas de Sonda Molecular , Unión Proteica , Homología de Secuencia de Ácido Nucleico , Triticum/genética
16.
FEBS Lett ; 239(2): 319-23, 1988 Nov 07.
Artículo en Inglés | MEDLINE | ID: mdl-3181434

RESUMEN

A nuclear protein(s), HBP-2, that binds to the upstream region of the wheat histone H4 gene was identified from a fractionated nuclear extract of wheat germ by DNase I footprinting. The DNase I-protected region contained the conserved nonameric motif, CATCCAACG. Cross-competition experiments that used the mobility shift assay showed that this nuclear protein(s) binds specifically to the upstream sequence that has been postulated to be a cis element of the wheat H3 gene. Our findings suggest that this DNA-binding protein(s) may be a trans-acting factor in the regulation of the transcription of wheat histone genes.


Asunto(s)
Proteínas de Unión al ADN/metabolismo , Genes , Plantas/genética , Secuencia de Bases , ADN/genética , ADN/metabolismo , Desoxirribonucleasa I , Datos de Secuencia Molecular , Plantas/metabolismo , Triticum/genética , Triticum/metabolismo
17.
Br J Pharmacol ; 99(1): 152-6, 1990 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-1691941

RESUMEN

1. The effects of capsaicin (Cap) on contractions of ring segments of rabbit ear artery induced by field stimulation were studied. 2. At low concentrations (0.3-3 microM) Cap caused transient enhancement and at higher concentrations (above 3 microM) inhibition of stimulation-induced contractions, without affecting noradrenaline (NA)-induced contractions. 3. In the continuous presence of high concentrations of Cap, rebound facilitation was observed after inhibition, and at this stage, Cap elicited less inhibition of the response. 4. Repeated application of Cap at 60 min intervals irreversibly desensitized the artery to the inhibitory effect of Cap. 5. Functional removal of the endothelium enhanced the facilitatory effect of low concentrations of Cap and attenuated its inhibitory effect. 6. Pretreatment with indomethacin abolished the facilitatory effect of Cap and enhanced its inhibitory effect, indicating that prostaglandins are involved in the action of Cap. The effect of indomethacin was more marked in preparations from which the endothelium had been removed. 7. Desensitization to substance P (SP) or substance K (SK), did not affect either the inhibitory or the facilitatory effect of Cap. 8. These results suggest that the dual effects of Cap on stimulation-induced contractions of rabbit ear artery may arise from the release of multiple mediators that act prejunctionally to modulate NA release. The stimulant effect seems to be mediated by prostanoids, while the inhibitory effect seems to be caused by a substance(s) that is not SP or SK. The possibility that the mediator is calcitonin gene-related peptide requires further study.


Asunto(s)
Capsaicina/farmacología , Músculo Liso Vascular/efectos de los fármacos , Animales , Arterias/efectos de los fármacos , Péptido Relacionado con Gen de Calcitonina/farmacología , Oído Externo/irrigación sanguínea , Estimulación Eléctrica , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/fisiología , Técnicas In Vitro , Indometacina/farmacología , Músculo Liso Vascular/fisiología , Neuroquinina A/farmacología , Norepinefrina/farmacología , Prostaglandinas/farmacología , Conejos , Flujo Sanguíneo Regional/efectos de los fármacos , Sustancia P/farmacología , Sistema Nervioso Simpático/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacos
18.
Br J Pharmacol ; 118(6): 1429-32, 1996 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8832068

RESUMEN

1. The effect of endothelin antagonists on endothelium-dependent contractions was studied in conditions of stimulated endothelium-derived contracting factor (EDCF) release and with exogenous activation of thromboxane A2-endoperoxide receptors in the rat aorta. 2. The incubation of aortic rings with N omega-nitro-L-arginine methyl ester (L-NAME) led to EDCF-mediated contraction upon stimulation with acetylcholine (24 +/- 3% of KCl contraction). When vessels were preincubated with bosentan, an endothelinA- and endothelinB-receptor antagonist, in addition to L-NAME, acetylcholine-induced contraction was reduced to 8 +/- 2% (P < 0.01) of KCl contractions. PD147953, a selective endothelinA-receptor antagonist, reduced the contraction to 14 +/- 4% (P < 0.05) of KCl contractions. 3. Bosentan preincubation produced a significant parallel rightward shift of the contractions to U46619, a selective thromboxane A2 receptor agonist. In contrast, PD147953 failed to exhibit any inhibitory effect on U46619 contractions. 4. These results suggest that endothelin antagonists inhibit EDCF-mediated contractions by blocking endothelinA receptors and that, in addition, bosentan antagonizes the direct stimulation of thromboxane A2 receptors.


Asunto(s)
Antagonistas de los Receptores de Endotelina , Endotelinas/antagonistas & inhibidores , Prostaglandinas/farmacología , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico , Animales , Aorta Torácica/efectos de los fármacos , Bosentán , Endotelio Vascular/fisiología , Técnicas In Vitro , Masculino , Contracción Muscular/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Endoperóxidos de Prostaglandinas Sintéticos/farmacología , Ratas , Ratas Endogámicas WKY , Receptores de Endotelina , Receptores de Tromboxanos/agonistas , Sulfonamidas/farmacología , Tromboxano A2/análogos & derivados , Tromboxano A2/farmacología , Vasoconstrictores/farmacología
19.
Br J Pharmacol ; 100(3): 569-75, 1990 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-2167736

RESUMEN

1. Adenosine-induced dilatation of rat aorta was present in aorta taken from 4 week-old rats, attenuated with increase in age of rats to 8 weeks, and was virtually absent in the aorta from 12 week-old rats. 2. Removal of the endothelium by mechanical rubbing attenuated adenosine-induced dilatation. 3. Haemoglobin and methylene blue partly reversed the adenosine-induced endothelium-dependent dilatation. 4. The order of potency of adenosine derivatives was 5'-(N-ethylcarboxamido)adenosine (NECA) greater than 2-phenylaminoadenosine (CV-1808) greater than 2-chloroadenosine greater than N6-([R]-[-]-phenylisopropyl)adenosine (R-PIA) greater than adenosine greater than N6-cyclohexyladenosine (CHA) greater than N6-([S]-[+]-phenylisopropyl)adenosine (S-PIA), indicating that adenosine receptors mediating the dilatation are of the A2 subtype. 5. [3H]-NECA bound to preparations of membranes from rats of 4 weeks old; it was displaced more effectively by NECA and the A2 ligand CV-1808 than by the A1 ligands CHA and S-PIA. ligands CHA and S-PIA. 6. The number but not affinity of specific binding sites for NECA decreased considerably with increase in age of rats to 8 weeks, and binding sites for [3H]-NECA were hardly detected in membrane preparations from rats of 20 weeks old. 7. Adenosine caused a marked increase in cyclic GMP production, but did not induce an increase in the cyclic AMP level. 8. This increase in cyclic GMP production induced by adenosine was abolished by methylene blue or 8-phenyltheophylline, or by removal of the endothelium. 9. The age-associated decrease in adenosine-induced dilatation was found to be associated with a reduction in the formation of cyclic GMP, but not of cyclic AMP. 10. These results suggest that adenosine causes dilatation via A2 receptors by inducing production of an endothelium-derived relaxing factor (EDRF), which in turn stimulates soluble guanylate cyclase, and so increases production of cyclic GMP. It is also suggested that the main reason for the age-associated decrease in adenosine-induced dilatation is a decrease in the number of A2-receptors or the ability of the endothelium to produce EDRF, leading to decreased production of cyclic GMP.


Asunto(s)
Adenosina/farmacología , Envejecimiento/fisiología , GMP Cíclico/fisiología , Músculo Liso Vascular/efectos de los fármacos , Vasodilatación/fisiología , Adenosina/análogos & derivados , Adenosina-5'-(N-etilcarboxamida) , Animales , Aorta Torácica/efectos de los fármacos , Aorta Torácica/metabolismo , AMP Cíclico/metabolismo , Técnicas In Vitro , Masculino , Músculo Liso Vascular/metabolismo , Ratas , Ratas Endogámicas , Receptores Purinérgicos/efectos de los fármacos , Receptores Purinérgicos/metabolismo
20.
J Atheroscler Thromb ; 2(2): 87-95, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-9225215

RESUMEN

Heparin administration to diabetic rats caused no change in VLDL, an increase in IDL and a decrease in LDL on electrophoretic analysis of plasma lipoproteins, while the administration to control rats markedly decreased VLDL and increased IDL and LDL. Both hepatic triglyceride lipase (HTGL) and lipoprotein lipase (LPL) activities in the postheparin plasma were lower in the diabetic rats than in the controls, and the reduction of HTGL activity was greater than that of LPL activity in the diabetic rats. The LPL activity in the adipose tissue was lower in the diabetic rats than in the controls, but the activities in the cardiac and skeletal muscles were similar in the two rats. The HTGL-catalyzed fatty acid (FA) releases from the diabetic VLDL and IDL were lower than those from the normal rat VLDL and IDL, while the LPL-catalyzed FA release in the diabetic rats was not different from those in the controls. The decreases in LPL and HTGL activities and the markedly impaired susceptibility of IDL to HTGL coincide well with the postheparin changes in plasma lipoproteins in diabetic rats, an increase in IDL and a decrease in LDL.


Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Hiperlipidemias/enzimología , Lipasa/fisiología , Lipoproteína Lipasa/fisiología , Lipoproteínas/metabolismo , Tejido Adiposo/enzimología , Animales , Anticoagulantes/farmacología , Ácidos Grasos/metabolismo , Heparina/farmacología , Técnicas In Vitro , Masculino , Músculos/enzimología , Ratas , Ratas Sprague-Dawley
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA